Presentation is loading. Please wait.

Presentation is loading. Please wait.

Post-treatment management of esophageal cancers: Surgical considerations Stephen Swisher, MD PhD Robert F. Fly Professor of Surgical Oncology Chairman,

Published byEverett Henry Modified over 8 years ago

Similar presentations

Presentation on theme: "Post-treatment management of esophageal cancers: Surgical considerations Stephen Swisher, MD PhD Robert F. Fly Professor of Surgical Oncology Chairman,"— Presentation transcript:

1 Post-treatment management of esophageal cancers: Surgical considerations Stephen Swisher, MD PhD Robert F. Fly Professor of Surgical Oncology Chairman, Department of Thoracic and Cardiovascular Surgery MD Anderson Cancer Center Houston, TX

2

3 Role of surgery for treatment of tumor recurrence after Role of surgery for treatment of tumor recurrence after Esophagectomy (without chemoXRT)Esophagectomy (without chemoXRT) surgical options for recurrent tumor after primary esophagectomy surgical options for recurrent tumor after primary esophagectomy Colon Jejunum

4 Role of surgery for treatment of tumor recurrence after Role of surgery for treatment of tumor recurrence after Esophagectomy (without chemoXRT)Esophagectomy (without chemoXRT) surgical options for recurrent tumor after primary esophagectomy surgical options for recurrent tumor after primary esophagectomy

5 Role of surgery for treatment of tumor recurrence after Role of surgery for treatment of tumor recurrence after Esophagectomy (without chemoXRT)Esophagectomy (without chemoXRT) surgical options for recurrent tumor after primary esophagectomy surgical options for recurrent tumor after primary esophagectomy

6 Role of surgery for treatment of tumor recurrence after Role of surgery for treatment of tumor recurrence after Esophagectomy (without chemoXRT)Esophagectomy (without chemoXRT) surgical options for recurrent tumor after primary esophagectomy surgical options for recurrent tumor after primary esophagectomy

7 Role of surgery for treatment of tumor recurrence after Role of surgery for treatment of tumor recurrence after Esophagectomy (without chemoXRT)Esophagectomy (without chemoXRT) surgical options for recurrent tumor after primary esophagectomy surgical options for recurrent tumor after primary esophagectomy

8 Role of surgery for treatment of tumor recurrence after Role of surgery for treatment of tumor recurrence after Definitive chemoradiationDefinitive chemoradiation Is surgery possible after chemoradiation Is surgery possible after chemoradiation What are potential risks and benefits What are potential risks and benefits

9 Role of surgery for treatment of tumor recurrence after Role of surgery for treatment of tumor recurrence after Definitive chemoradiationDefinitive chemoradiation Is surgery possible after chemoradiation Is surgery possible after chemoradiation What are potential risks and benefits What are potential risks and benefits

10 Role of surgery for treatment of tumor recurrence after Role of surgery for treatment of tumor recurrence after Pre-op chemo-XRT- in patients who recur after an complete clinical response.Pre-op chemo-XRT- in patients who recur after an complete clinical response.

11 Role of surgery for treatment of tumor recurrence after Role of surgery for treatment of tumor recurrence after Pre-op chemo-XRT- in patients who recur after an complete clinical response.Pre-op chemo-XRT- in patients who recur after an complete clinical response.

12 Role of surgery for treatment of tumor recurrence after Role of surgery for treatment of tumor recurrence after Pre-op chemo-XRT- in patients who recur after an complete clinical response.Pre-op chemo-XRT- in patients who recur after an complete clinical response.

13 Role of surgery for treatment of tumor recurrence after chemoradiation Role of surgery for treatment of tumor recurrence after chemoradiation Salvage esophagectomySalvage esophagectomy What is it; Who are potential candidates; Survival benefit What is it; Who are potential candidates; Survival benefit

14 Role of surgery for treatment of tumor recurrence after chemoradiation Role of surgery for treatment of tumor recurrence after chemoradiation Salvage esophagectomySalvage esophagectomy What is it; Who are potential candidates; Survival benefit What is it; Who are potential candidates; Survival benefit

15 Role of surgery for treatment of tumor recurrence after chemoradiation Role of surgery for treatment of tumor recurrence after chemoradiation Salvage esophagectomySalvage esophagectomy What is it; Who are potential candidates; Survival benefit What is it; Who are potential candidates; Survival benefit

16 Role of surgery for treatment of tumor recurrence after chemoradiation Role of surgery for treatment of tumor recurrence after chemoradiation Salvage esophagectomySalvage esophagectomy What is it; Who are potential candidates; Survival benefit What is it; Who are potential candidates; Survival benefit RTOG 0246

17 Role of surgery for treatment of tumor recurrence after chemoradiation Role of surgery for treatment of tumor recurrence after chemoradiation Salvage esophagectomySalvage esophagectomy What is it; Who are potential candidates; Survival benefit What is it; Who are potential candidates; Survival benefit

18 Role of surgery for treatment of tumor recurrence after chemoradiation Role of surgery for treatment of tumor recurrence after chemoradiation Salvage esophagectomySalvage esophagectomy What is it; Who are potential candidates; Survival benefit What is it; Who are potential candidates; Survival benefit RTOG 0246

19 Q1

20 Repeat endoscopy 1 year after surgery to rule out residual Barrett’s or dysplasiaRepeat endoscopy 1 year after surgery to rule out residual Barrett’s or dysplasia No CT Scan, CXR or PET scan unless symptoms because of low likelihood of distant mets with T1N0, LVI negativeNo CT Scan, CXR or PET scan unless symptoms because of low likelihood of distant mets with T1N0, LVI negative

21 Repeat endoscopy 1 year after surgery to rule out residual Barrett’s or dysplasiaRepeat endoscopy 1 year after surgery to rule out residual Barrett’s or dysplasia No CT Scan, CXR or PET scan unless symptoms because of low likelihood of distant mets with T1N0, LVI negativeNo CT Scan, CXR or PET scan unless symptoms because of low likelihood of distant mets with T1N0, LVI negative

22 Q2

23 Path CR – no diff. in relapse locations Path CR – no diff. in relapse locations What we do: if no sxs - CT scan +/- EGD q6 mos x 4 then yrly (only asx group to help – LN, ? Anast Rec) What we do: if no sxs - CT scan +/- EGD q6 mos x 4 then yrly (only asx group to help – LN, ? Anast Rec)

24 Q3

25 Salvage Esophagectomy Salvage Esophagectomy no metastatic disease,no metastatic disease, regional LNregional LN no other curative Rxno other curative Rx

26 Q4

27 Since unable to tolerate surgery Since unable to tolerate surgery few therapeutic options if Asymtomatic –few therapeutic options if Asymtomatic – PE q 6 monthsPE q 6 months If symptomatic If symptomatic studies to assess for palliative Rx –Stents, EMR, PDT, Brachytherapystudies to assess for palliative Rx –Stents, EMR, PDT, Brachytherapy

28 State of the Art

29 Summary of today’s state of the art Summary of today’s state of the art Asymptomatic recurrences that can be helped : Asymptomatic recurrences that can be helped : CT Scans +/- Endoscopy q 6 mos x 4 then q yearCT Scans +/- Endoscopy q 6 mos x 4 then q year Anastomotic RecurrenceAnastomotic Recurrence Salvage Surgery: Colonic/Jejunal conduit Salvage Surgery: Colonic/Jejunal conduit CRT CRT Local/Distant LNLocal/Distant LN Surgery or CRT (non-radiated area) Surgery or CRT (non-radiated area)

30 What new modalities are on the horizon in the next 5 years? the next 10 years? What new modalities are on the horizon in the next 5 years? the next 10 years? Novel Molecular Therapeutics Novel Molecular Therapeutics PET Scan identification of non-responders to allow additional treatment prior to resection PET Scan identification of non-responders to allow additional treatment prior to resection

31

Download ppt "Post-treatment management of esophageal cancers: Surgical considerations Stephen Swisher, MD PhD Robert F. Fly Professor of Surgical Oncology Chairman,"

Similar presentations

Is there a role for surgery in metastatic colorectal cancer?

Is there a role for surgery in metastatic colorectal cancer?
Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD

Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD
Follow-up of GI Cancers Dr. Marianne Taylor BC Cancer Agency – CSI November 29, 2003.

Follow-up of GI Cancers Dr. Marianne Taylor BC Cancer Agency – CSI November 29, 2003.
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.

Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.

Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.
Amy Schindler 10/18/10.  Endoscopic appearance: Early cancers: superficial plaque, nodule, or ulceration Advanced lesions: strictures, ulcerated masses,

Amy Schindler 10/18/10.  Endoscopic appearance: Early cancers: superficial plaque, nodule, or ulceration Advanced lesions: strictures, ulcerated masses,
Nasal cavity, paranasal sinuses, orbita and anterior skull base Moderator: Jeffrey Myers MD PhD Professor and Deputy Chair for Research Department of Head.

Nasal cavity, paranasal sinuses, orbita and anterior skull base Moderator: Jeffrey Myers MD PhD Professor and Deputy Chair for Research Department of Head.
Rectal Cancer: A Complete Clinical Response…Now what?

Rectal Cancer: A Complete Clinical Response…Now what?
Management of Pancreato- biliary Malignancy: Medical Oncology Perspective Robert A. Wolff, MD Professor of Medicine Department of GI Medical Oncology.

Management of Pancreato- biliary Malignancy: Medical Oncology Perspective Robert A. Wolff, MD Professor of Medicine Department of GI Medical Oncology.
Borderline Resectable Pancreatic Carcinoma

Borderline Resectable Pancreatic Carcinoma
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.

Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Joint Hospital Surgical Grand Round KL FOK NDH/AHNH Department of Surgery.

Joint Hospital Surgical Grand Round KL FOK NDH/AHNH Department of Surgery.
Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.

Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.
Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease Jose G. Guillem, MD, MPH Department of Surgery.

Defining the Colorectal Surgeons role in patients with colorectal cancer and limited metastatic disease Jose G. Guillem, MD, MPH Department of Surgery.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.

Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Joint Hospital Surgical Grand Round 21 st July, 2012 RH.

Joint Hospital Surgical Grand Round 21 st July, 2012 RH.

Similar presentations

Ads by Google